MS News: October 2016

Highlight!

1. Influenza, Vaccinations, MS
2. Brain cognitive exhaustion is real for people with Multiple Sclerosis

Research

1. Multiple Sclerosis: Current Status of Research and Treatment
2. Bloodsucking parasitic hookworms could help make millions of people healthier: study
3. B cells as antigen presenting cells
4. β2-Adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple …
5. Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis
6. Optical Coherence Tomography in Multiple Sclerosis
7. Effects of different exercise modalities on ataxia in multiple sclerosis patients
8. Neuroinflammatory component of gray matter pathology in multiple sclerosis
9. A correlation study between multiple sclerosis and type 1 diabetes incidences
10. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging
11. Multiple system atrophy masking multiple sclerosis
12. Optic neuritis as an early sign of multiple sclerosis
13. Degree of Posture Difficulties in MS Linked to Areas of Nervous System Most Damaged by Disease
14. Selexis to Provide ImmuNext with Cell Lines for Research into Treatment for MS, Autoimmune Diseases
15. ‘Rare’ Molecule in Immune System Turns Out to Be Common, and May Be Part of What Goes Wrong in MS
16. Study of Myelin-producing Cells a Step Forward for MS, Other Neurological Disorders
17. Papathanasopoulos Multiple Sclerosis, Cannabinoids, And Cognition

Clinical Trials

1. Cytoxan In Multiple Sclerosis
2. Biogen Quietly Abandons a Key Next-Gen Multiple Sclerosis Drug
3. Opexa Therapeutics Anticipated Tclena Multiple Sclerosis (MS) Drug Fails Clinical Trial Endpoints
4. On the ropes, Opexa shares blasted by PhIIb multiple sclerosis trial flop
5. AXIM Moving Ahead with Testing of Cannabinoid Products, Including Chewing Gum for MS Patients
6. MNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS
7. GNS Unveils Platform to Predict New Therapy’s Likely Success in Real World at ISPOR
8. Getting More Blacks and Other Minority MS Patients into Clinical Studies Is Goal of ACP Project

Treatment News

1. Tecfidera Continued to Lead in the Oral Multiple Sclerosis Market
2. Study shows Lemtrada improves disability in relapsing remitting MS
3. Tysabri May Be More Effective Than Gilenya at Reducing Disease Activity in MS Patients, Study Says
4. Biogen’s Tecfidera, Amgen’s Enbrel tell a tale of pricing power and weakness
5. Laquinimod for Reducing Thalamic Damage in Multiple Sclerosis
6. Botulinum toxin therapy for treatment of spasticity in multiple sclerosis
7. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic
8. Medical Marijuana in the Form of Controlled-dose Capsules Now Available in New York
9. Biomarkers: The Future of Multiple Sclerosis Treatment
10. Multiple sclerosis: microRNA levels may serve as biomarker for treatment response
11. Reduces fatigue by using Andrographis paniculata: A Case of Multiple Sclerosis Patients
12. Glatiramer acetate in combination with minocycline in patients with relapsing
13. Relapses and Dislike of Needles Among Reasons MS Patients Stop Betaferon Treatment

Stem Cell Treatment

1. Umbilical Cord Stem Cells Work to Restore Immune System Balance in Early Study
2. Umbilical cord tissue stem cells can effectively reduce abnormal immune system activity in multiple …

General news

1. Primary care management of multiple sclerosis
2. Direct Nerve Stimulation Can Help Some MS Symptoms
3. Shake, Rattle, and Spill? Tremors in MS
4. MS, Osteoporosis and Men – What a Guy Needs to Know
5. Icy Cold Fingers: MS Broke My Thermostat!
6. Multiple Sclerosis and White Blood Cell Count
7. Multiple Sclerosis: Theory and Practice for Nurses

Mental & Emotional Health

1. 7 Strategies for Taking Control of MS Anxiety

Diet

1. How an MS Diagnosis Impacts Your Diet

2. Follow a Healthy Diet for Multiple Sclerosis

Exercise

1. Effects of different exercise modalities on ataxia in multiple sclerosis patients

Lifestyle

1. Jack Osbourne Reveals What He’s Learned About Marriage, Launches New MS Web Series
2. Stop Smoking
3. Characterization of Long-Term Multiple Sclerosis Disability

4. Smyle Mouse Relies on Facial Gestures to Let Users Control Their Computer

When You’ve Just Been Diagnosed

1. Where Does MS Begin?

2. Center of Neuroimmunology and Multiple Sclerosis

News posted on Barts MS Blog

1. Alemtuzumab and the innate immune cells
2. Alemtuzumab and the forgotten little details
3. #ClinicSpeak & #OffLabel: alemtuzumab
4. More evidence for the value of Generic Cladribine
5. laquinimod blocking experimental progression
6. Avonex and spinal cord atrophy
7. Remyelination enhancement by clemastine
8. Asthma drug for Remyelination
9. #ClinicSpeak & #OffLabel: rituximab in Sweden
10. Cannabis controlling spasticity
11. Antigen-specific therapy shows nothing
12. #ClinicSpeak & #NeuroSpeak: not all immunosuppressives are made equal
13. #ClinicSpeak: bone health in MS
14. #ClinicSpeak: What about PPMS?
15. #ClinicSpeak: what’s in a name?
16. #ClinicSpeak & #ResearchSpeak: will my disabilities improve?
17. #ResearchSpeak: INSPIRE TRIAL RESULTS
18. #BrainHealth: on how-not-to-do-it
19. Synapses are damaged in MS
20. Stem cells into the Brain
21. EPO and failure to stop MS occurring
22. Neuroprotection from ECTRIMS2016
23. #ResearchSpeak: ECTRIMS highlight
24. Needles, haystacks, and primary progressive MS
25. Exercise can’t be associated with reduced risk

Business News

1. Reconsidering the Economic Value of Multiple Sclerosis Therapies
2. Biogen Inc. Expected to Earn FY2019 Earnings of $24.41 Per Share (BIIB)
3. Biogen Stops Developing MT-1303 (Amiselimod) for Multiple Sclerosis According To Quarter III
4. Upbeat 3rd-qtr for Sanofi pushes shares higher
5. Sanofi Gains Boost from MS Treatments as Diabetes Drug Lantus Flounders
6. Multiple Sclerosis Global Market 2016 Analysis and Forecast to 2021
7. FDA approval could be delayed for Sanofi Genzyme’s next blockbuster
8. Autoimmune Diseases Treatment Market to Register a Strong Growth By 2015 to 2021
9. Celgene Reports Third Quarter 2016 Operating and Financial Results

Videos

1. Cognitive Dysfunction in Multiple Sclerosis (MS) Lecture by OhioHealth
2. When and how to use a walking aid in Multiple Sclerosis
3. Multiple Sclerosis – Stem Cell Patient
4. Download Attitude Is Everything: My Multiple Sclerosis Story [PDF]

© Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me, 2011-2016. Unauthorised use and/or duplication of this material without express and written permission from this blog’s author and/or owner are strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me with appropriate and specific direction to the original content.